The role of oncolytic virus immunotherapies to subvert cancer immune evasion
Despite huge economic and intellectual investments, developing effective cancer treatments continues to be an overarching challenge. Engineered oncolytic viruses (OVs) present self-amplifying immunotherapy platforms capable of preferential cytotoxicity to cancer cells and simultaneous activation of...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2015-02, Vol.11 (4), p.675-689 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 689 |
|---|---|
| container_issue | 4 |
| container_start_page | 675 |
| container_title | Future oncology (London, England) |
| container_volume | 11 |
| creator | Workenhe, Samuel T Verschoor, Meghan L Mossman, Karen L |
| description | Despite huge economic and intellectual investments, developing effective cancer treatments continues to be an overarching challenge. Engineered oncolytic viruses (OVs) present self-amplifying immunotherapy platforms capable of preferential cytotoxicity to cancer cells and simultaneous activation of host anti-tumor immunity. In preclinical studies, OVs are showing potent therapeutic effects when used in combination with other immune therapy strategies. In the clinic, the immunotherapeutic effects of OVs are showing promising results. Here we review current strategies for engineering OVs, and present a perspective of future directions within a discussion of the current outcomes of combinatorial approaches with other cancer immunotherapy platforms. |
| doi_str_mv | 10.2217/fon.14.254 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1872832492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A414867714</galeid><sourcerecordid>A414867714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-216626f8b1a644a0eeda60779721b24a30f41ab3f97413d7966a3abba41c32293</originalsourceid><addsrcrecordid>eNqF0U1rFTEUBuAglrZWN_4ACbgRYa75OJPMLEuxVbjQTV2HTO6JTZlJrsnMhf77pky1KAXJIh8853DCS8h7zjZCcP3Fp7jhsBEtvCKnXAM0nWT8dT2D7hulejghb0q5Ywy0bNkxORGt6hQX_JRsb26R5jQiTZ6m6NJ4PwdHDyEvhYZpWmKabzHbfcBC50TLMhwwz9TZ6DCvAikebAkpviVH3o4F3z3tZ-TH5debi2_N9vrq-8X5tnGgxNwIrpRQvhu4VQCWIe6sYlr3WvBBgJXMA7eD9L0GLne6V8pKOwwWuJNC9PKMfFr77nP6tWCZzRSKw3G0EdNSDO-06KSAXvyfqlYxUG0vK_34D71LS471I1XplgmmQDyrn3ZEE6JPc7busak5Bw6d0ppDVZsXVF07nIJLEX2o738VfF4LXE6lZPRmn8Nk873hzDymbGrKhoOpKVf84WnSZZhw94f-jrUCtQK_zEvG4gLWuMx6qxXBhYgvdX4AgmWyPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1675020642</pqid></control><display><type>article</type><title>The role of oncolytic virus immunotherapies to subvert cancer immune evasion</title><source>MEDLINE</source><source>PubMed Central</source><creator>Workenhe, Samuel T ; Verschoor, Meghan L ; Mossman, Karen L</creator><creatorcontrib>Workenhe, Samuel T ; Verschoor, Meghan L ; Mossman, Karen L</creatorcontrib><description>Despite huge economic and intellectual investments, developing effective cancer treatments continues to be an overarching challenge. Engineered oncolytic viruses (OVs) present self-amplifying immunotherapy platforms capable of preferential cytotoxicity to cancer cells and simultaneous activation of host anti-tumor immunity. In preclinical studies, OVs are showing potent therapeutic effects when used in combination with other immune therapy strategies. In the clinic, the immunotherapeutic effects of OVs are showing promising results. Here we review current strategies for engineering OVs, and present a perspective of future directions within a discussion of the current outcomes of combinatorial approaches with other cancer immunotherapy platforms.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon.14.254</identifier><identifier>PMID: 25686121</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Animals ; Biomedical engineering ; cancer immunotherapy ; Cancer research ; Cancer treatment ; Combined Modality Therapy ; Health aspects ; Humans ; Immune Tolerance - immunology ; Immunologic Surveillance ; Immunotherapy - methods ; Neoplasms - genetics ; Neoplasms - immunology ; Neoplasms - metabolism ; Neoplasms - therapy ; Oncolytic Virotherapy - methods ; oncolytic virus ; Oncolytic Viruses - genetics ; Oncolytic Viruses - immunology ; Tumor Escape - genetics ; Tumor Escape - immunology ; Virus Replication - immunology</subject><ispartof>Future oncology (London, England), 2015-02, Vol.11 (4), p.675-689</ispartof><rights>COPYRIGHT 2015 Future Medicine Ltd.</rights><rights>2015 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-216626f8b1a644a0eeda60779721b24a30f41ab3f97413d7966a3abba41c32293</citedby><cites>FETCH-LOGICAL-c462t-216626f8b1a644a0eeda60779721b24a30f41ab3f97413d7966a3abba41c32293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25686121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Workenhe, Samuel T</creatorcontrib><creatorcontrib>Verschoor, Meghan L</creatorcontrib><creatorcontrib>Mossman, Karen L</creatorcontrib><title>The role of oncolytic virus immunotherapies to subvert cancer immune evasion</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Despite huge economic and intellectual investments, developing effective cancer treatments continues to be an overarching challenge. Engineered oncolytic viruses (OVs) present self-amplifying immunotherapy platforms capable of preferential cytotoxicity to cancer cells and simultaneous activation of host anti-tumor immunity. In preclinical studies, OVs are showing potent therapeutic effects when used in combination with other immune therapy strategies. In the clinic, the immunotherapeutic effects of OVs are showing promising results. Here we review current strategies for engineering OVs, and present a perspective of future directions within a discussion of the current outcomes of combinatorial approaches with other cancer immunotherapy platforms.</description><subject>Animals</subject><subject>Biomedical engineering</subject><subject>cancer immunotherapy</subject><subject>Cancer research</subject><subject>Cancer treatment</subject><subject>Combined Modality Therapy</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immune Tolerance - immunology</subject><subject>Immunologic Surveillance</subject><subject>Immunotherapy - methods</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - therapy</subject><subject>Oncolytic Virotherapy - methods</subject><subject>oncolytic virus</subject><subject>Oncolytic Viruses - genetics</subject><subject>Oncolytic Viruses - immunology</subject><subject>Tumor Escape - genetics</subject><subject>Tumor Escape - immunology</subject><subject>Virus Replication - immunology</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqF0U1rFTEUBuAglrZWN_4ACbgRYa75OJPMLEuxVbjQTV2HTO6JTZlJrsnMhf77pky1KAXJIh8853DCS8h7zjZCcP3Fp7jhsBEtvCKnXAM0nWT8dT2D7hulejghb0q5Ywy0bNkxORGt6hQX_JRsb26R5jQiTZ6m6NJ4PwdHDyEvhYZpWmKabzHbfcBC50TLMhwwz9TZ6DCvAikebAkpviVH3o4F3z3tZ-TH5debi2_N9vrq-8X5tnGgxNwIrpRQvhu4VQCWIe6sYlr3WvBBgJXMA7eD9L0GLne6V8pKOwwWuJNC9PKMfFr77nP6tWCZzRSKw3G0EdNSDO-06KSAXvyfqlYxUG0vK_34D71LS471I1XplgmmQDyrn3ZEE6JPc7busak5Bw6d0ppDVZsXVF07nIJLEX2o738VfF4LXE6lZPRmn8Nk873hzDymbGrKhoOpKVf84WnSZZhw94f-jrUCtQK_zEvG4gLWuMx6qxXBhYgvdX4AgmWyPg</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Workenhe, Samuel T</creator><creator>Verschoor, Meghan L</creator><creator>Mossman, Karen L</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20150201</creationdate><title>The role of oncolytic virus immunotherapies to subvert cancer immune evasion</title><author>Workenhe, Samuel T ; Verschoor, Meghan L ; Mossman, Karen L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-216626f8b1a644a0eeda60779721b24a30f41ab3f97413d7966a3abba41c32293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Biomedical engineering</topic><topic>cancer immunotherapy</topic><topic>Cancer research</topic><topic>Cancer treatment</topic><topic>Combined Modality Therapy</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immune Tolerance - immunology</topic><topic>Immunologic Surveillance</topic><topic>Immunotherapy - methods</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - therapy</topic><topic>Oncolytic Virotherapy - methods</topic><topic>oncolytic virus</topic><topic>Oncolytic Viruses - genetics</topic><topic>Oncolytic Viruses - immunology</topic><topic>Tumor Escape - genetics</topic><topic>Tumor Escape - immunology</topic><topic>Virus Replication - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Workenhe, Samuel T</creatorcontrib><creatorcontrib>Verschoor, Meghan L</creatorcontrib><creatorcontrib>Mossman, Karen L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Workenhe, Samuel T</au><au>Verschoor, Meghan L</au><au>Mossman, Karen L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of oncolytic virus immunotherapies to subvert cancer immune evasion</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2015-02-01</date><risdate>2015</risdate><volume>11</volume><issue>4</issue><spage>675</spage><epage>689</epage><pages>675-689</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Despite huge economic and intellectual investments, developing effective cancer treatments continues to be an overarching challenge. Engineered oncolytic viruses (OVs) present self-amplifying immunotherapy platforms capable of preferential cytotoxicity to cancer cells and simultaneous activation of host anti-tumor immunity. In preclinical studies, OVs are showing potent therapeutic effects when used in combination with other immune therapy strategies. In the clinic, the immunotherapeutic effects of OVs are showing promising results. Here we review current strategies for engineering OVs, and present a perspective of future directions within a discussion of the current outcomes of combinatorial approaches with other cancer immunotherapy platforms.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>25686121</pmid><doi>10.2217/fon.14.254</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2015-02, Vol.11 (4), p.675-689 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1872832492 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Biomedical engineering cancer immunotherapy Cancer research Cancer treatment Combined Modality Therapy Health aspects Humans Immune Tolerance - immunology Immunologic Surveillance Immunotherapy - methods Neoplasms - genetics Neoplasms - immunology Neoplasms - metabolism Neoplasms - therapy Oncolytic Virotherapy - methods oncolytic virus Oncolytic Viruses - genetics Oncolytic Viruses - immunology Tumor Escape - genetics Tumor Escape - immunology Virus Replication - immunology |
| title | The role of oncolytic virus immunotherapies to subvert cancer immune evasion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A32%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20oncolytic%20virus%20immunotherapies%20to%20subvert%20cancer%20immune%20evasion&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Workenhe,%20Samuel%20T&rft.date=2015-02-01&rft.volume=11&rft.issue=4&rft.spage=675&rft.epage=689&rft.pages=675-689&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon.14.254&rft_dat=%3Cgale_proqu%3EA414867714%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1675020642&rft_id=info:pmid/25686121&rft_galeid=A414867714&rfr_iscdi=true |